Heteroaryl-aryl ureas as IGF-1 receptor antagonists
US6337338B1 · kind B1 · utility
32Cited by
4References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 15, 1999 |
| Grant date | Jan 8, 2002 |
| Priority date | — |
| Expiry date | Dec 15, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treating diseases associated with the activity of the insulin growth factor-1 receptor (IGF-1R), such as cancer, are provided. Methods for inhibiting cell growth and proliferation, especially of tumor cells, and promoting apoptosis are also provided. Each of these methods employs the use of a heteroaryl-aryl urea compound as an antagonist for IGF-1R.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.